-
Get ready for the latest presentations on evidence-based methods and practical tips for your practice at the two 2012 conferences for Contraceptive Technology.
-
In October 2011, Ohio became the seventh state to use new authority under the Affordable Care Act (ACA) to extend coverage for family planning services to women and men with incomes well above the state's standard Medicaid income eligibility ceilings.
-
The next file in your inbox is for a 35-year-old woman who has had recurrent vaginal infections. In the past year, she has had numerous episodes of itching, burning, and abnormal discharge.
-
Good news: In a year when reports of financial downturns have dominated the headlines, results of the Contraceptive Technology Update 2011 Salary Survey reflect a holding pattern in salary levels.
-
-
In an epidemiologic analysis of SEER data, middle-aged patients with early-stage disease who opted for active surveillance rather than retroperitoneal lymph node dissection experienced a greater rate of second malignancy. The investigators speculate that this may relate to increased radiation exposure (multiple CT scans) and a greater likelihood of subsequent chemotherapy use.
-
In a randomized, double-blind, placebo-controlled trial, clonidine and venlafaxine both proved superior to placebo in reducing hot flashes in breast cancer patients. The study was insufficiently powered to prove superiority of one drug over the other. However, venlafaxine produced earlier reductions and it appeared clonidine had more sustained effect (i.e., at 12 weeks of treatment).
-
A 66-year-old postmenopausal retired teacher went to her primary care physician because she found a lump in her right breast during a routine bath.
-
From a large cohort of women followed prospectively and with an adjunct meta-analysis of existing evaluable studies, a clearly demonstrated, nearly universal (i.e., across tumor types) incremental increase in cancer incidence was observed with advancing height.
-
Medication poisonings in children; rosuvastatin vs atorvastatin for atherosclerosis; saw palmetto for prostate symptoms; using atypical antipsychotics for off-label indications in adults; and FDA actions.